Multiomics Market

The multiomics market is projected to reach USD 5.70 billion by 2031 from USD 3.18 billion in 2026, at a CAGR of 12.3%. The growth of the multiomics market is driven by the rising use of multiomics in precision medicine and disease stratification, along with the increasing accessibility of high-quality, integrated omics data for research. Additionally, rapid adoption of single-cell and spatial multiomics is expected to support market growth.

The global multiomics market is competitive, with top players such as 10x Genomics, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Oxford Nanopore Technologies plc (UK), and Bruker Corporation (US) leading the market. The market players have adopted various strategies, such as approvals and launches of new products and services, acquisitions, agreements, collaborations, partnerships, and geographical expansions, to strengthen their position in the global multiomics market.

To know about the assumptions considered for the study download the pdf brochure

10x Genomics, Inc. (US)

10x Genomics is a leading player in the multiomics market, particularly in single-cell and spatial multiomics technologies. The company offers platforms such as Chromium and Visium that enable high-resolution analysis of cellular heterogeneity, gene expression patterns, and tissue organization. Its solutions support integrated transcriptomic, genomic, and spatial profiling workflows used in oncology, immunology, neuroscience, developmental biology, and drug discovery research. The company's focus on expanding single-cell and spatial biology capabilities continues to strengthen its position in advanced multiomics research.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is a major participant in the multiomics market, offering a broad portfolio of analytical instruments, sequencing solutions, mass spectrometry platforms, sample preparation technologies, reagents, and informatics solutions. The company supports multiomics workflows spanning molecular characterization, proteomics, metabolomics, genomics, and translational research. Its integrated ecosystem enables pharmaceutical companies, biotechnology organizations, and academic institutions to perform comprehensive biological analysis across discovery and development workflows.

Illumina, Inc. (US)

Illumina is a prominent player in the multiomics market through its sequencing platforms, library preparation technologies, and genomic analysis solutions. The company's next-generation sequencing (NGS) technologies serve as a foundational component for multiomics workflows by enabling large-scale genomic and transcriptomic profiling. Illumina's sequencing ecosystem supports applications including precision medicine, oncology research, biomarker discovery, and systems biology studies.

Oxford Nanopore Technologies plc (UK)

Oxford Nanopore Technologies is a key contributor to the multiomics market through its nanopore sequencing platforms that enable real-time, long-read molecular analysis. The company's technologies support genomic, transcriptomic, and epigenomic profiling by providing direct sequencing capabilities and flexible workflows. Its portable and scalable sequencing platforms are increasingly adopted in research environments requiring rapid molecular characterization and decentralized multiomics analysis.

Market Ranking

The multiomics market demonstrates moderate consolidation, with leading companies capturing a significant share through differentiated technology platforms, broad product portfolios, and integrated workflow capabilities. Competitive positioning is primarily influenced by strengths in sequencing technologies, single-cell and spatial omics platforms, analytical instrumentation, bioinformatics solutions, and application-specific workflows.

10x Genomics, Inc. (US) maintains a strong position through its leadership in single-cell and spatial multiomics technologies, enabling high-resolution cellular and tissue-level analysis. Thermo Fisher Scientific Inc. (US) benefits from its extensive life science ecosystem comprising analytical instruments, sequencing solutions, mass spectrometry platforms, and research consumables. Illumina, Inc. (US) continues to hold a strong position through its sequencing technologies, which serve as a core enabling platform for genomics-driven multiomics applications. Oxford Nanopore Technologies plc (UK) differentiates itself through real-time long-read sequencing and portable sequencing solutions. Bruker Corporation (US) strengthens the market through advanced proteomics and metabolomics analytical platforms.

The remaining market consists of specialized spatial biology companies, bioinformatics providers, CROs, and emerging multiomics technology developers offering application-specific solutions. These players are expanding through innovation in integrated workflows, AI-enabled data analysis, cloud-based platforms, and collaborations with pharmaceutical companies, biotechnology firms, and academic research institutions.

Related Reports:

Multiomics Market by Offerings [Product (Instrument, Kits, Reagents), Service], Method (Epigenomics, Single Cell, Spatial), Technology [Sequencing, Proteomics (NGS, PCR, MS)], Workflow (Sample Prep), Application, Competition - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]